Bioz Has Partnered With RayBiotech to Bring Data and Transparency to Their User Experience

Bioz Badges - RayBiotech

Bioz, Inc., a Silicon Valley A.I. data company, is proud to announce a new partnership with RayBiotech, Inc., a pioneer of the planar cytokine array and multiplex immunoassays. By combining the latest advances in A.I., Bioz enables the research community, both in academia and in biopharma, to access real-world validated use-cases coming directly from scientific articles. By federating product use-cases, in the form of Bioz Stars product recommendations and article citation snippets, onto RayBiotech’s website, researchers benefit from enhanced transparency, greater confidence, and an overall more valuable user experience.

RayBiotech has developed the world’s largest library of array-validated sandwich antibody pairs, which allow for up to 1,000 proteins to be detected concurrently, or as few as 5 proteins in a highly cost-effective manner. RayBiotech also manufactures over 4,000 ELISA kits and offers a full-spectrum of CRO services and custom assay development. Founded in Atlanta, GA, RayBiotech is an ISO and CLIA certified company.

Research shows that product usage, as mentioned in peer-reviewed scientific articles, is the number one driver of the purchase of experimentation tools used for life science research and drug discovery. This insight becomes even more evident as the life science tool industry increasingly curates and markets peer-reviewed citations that mention their products. With its partnership with Bioz, RayBiotech now displays the most recent and relevant product citations on each of its website’s product pages, via dynamic Bioz Badges. These badges also feature the Bioz Stars score, an objective recommendation that is based on the concept of ZERO BIAS™, and full transparency. The recommendations have been generated by Bioz' proprietary A.I. software that has mined over 500 million pages of scientific text from peer-reviewed articles. Bioz badges are product-specific, objective, and they simplify the process of experiment planning and product selection.

"I am excited to partner with RayBiotech to provide their researchers with peer-reviewed product-specific data," said Dr. Karin Lachmi, co-founder and CSO of Bioz. "RayBiotech has a clear leadership position in antibody and ELISA products, which play a key role in many applications and assays. I am pleased that together, we are able to bring forth greater transparency and objectivity to their researchers by highlighting the published use of RayBiotech products, as documented in the latest scientific studies."

"Bioz is all about data and technology, and we are proud to add objective data about the use of our products to our website. Our users can now easily see where and when RayBiotech products have been used in published research,” said Valerie Jones, Director of Marketing at RayBiotech, adding that “we have seen a high-level of user interaction with Bioz Badges on our website, which highlights that the badges reinforce well-informed researcher purchase decisions.”

Helpful Links

Suggested Tweet: @RayBiotech leverages @Bioz A.I. software to bring transparency to its researchers and to ensure user confidence via unbiased product data. https://bit.ly/2WrMfg6

About Bioz, Inc.

Bioz is the world's most advanced A.I. search engine for life science experimentation, empowering scientists in biopharma and academia to accelerate their research towards new discoveries. Bioz guides scientists to the most-validated and cost-effective products to use in their experiments by providing them with evidence-based product recommendations. These recommendations have been reverse-engineered from real-world experiments, as described in over 500 million pages of scientific text from peer-reviewed articles. The result: Bioz.com, the world's most comprehensive source of life science product recommendations and experimentation guidance, covering over 300 million products, 50,000 suppliers, 16 million images, and over 7 billion protocol conditions and associated techniques, enabling researchers to work faster and more cost-effectively, generating more successful and impactful outcomes.

Bioz A.I. was developed by an experienced team of software engineers, led by A.I. experts from Microsoft and Google and Nobel Prize winners in chemistry. The technology incorporates proprietary cutting-edge NLP, ML, neural networks, deep learning, and domain-specific named-entity recognition, entity matching, and entity linking algorithms. What used to take scientists months, now takes them mere minutes with Bioz, 84x times faster than before. By accelerating the pace of experiments, Bioz increases the speed of drug discovery by as much as 56%, which translates into billions of research dollars saved. With objectivity, transparency, and trustworthiness, Bioz empowers researchers in the top 25 biopharma companies, and in more than 12,400 academic institutions in 196 countries. 

To learn more about the Bioz Partner Program, please reach out to partners@bioz.com.

About RayBiotech, Inc.

RayBiotech is the pioneer of the planar cytokine array, focusing on customizable, high-density multiplex immunoassays. With the world’s largest library of array-validated sandwich antibody pairs, RayBiotech’s arrays allow up to 1,000 proteins to be detected concurrently, or as few as 5 proteins in a highly cost-effective manner. RayBiotech also manufactures over 4,000 ELISA kits and offers a full spectrum of CRO services and custom assay development. Founded in Atlanta, GA, RayBiotech is an ISO-13485 and GMP/GLP certified company.

To learn more about RayBiotech’s products, please visit www.raybiotech.com.

Media Contact:
Daniel Levitt
Bioz, Inc.
pr@bioz.com

Source: Bioz, Inc.


Categories: Pharmaceuticals and Biotech, Biology

Tags: AI, bio-pharma, biology, biopharma, bioz, chemistry, experimentation, life science, machine learning, NLP, raybio, raybiotech


About Bioz, Inc.

View Website

Bioz is the world's most advanced A.I. search engine for life science experimentation, empowering scientists in biopharma and academia to accelerate their research towards new discoveries.